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We studied in vitro effects of glycogen synthase kinase 3b
(GSK3b)-inhibitor lithium on the growth of hepatocellular carci-
noma (HCC) cells. Lithium induced strong growth inhibition
(>70%) in 75% (n = 9 of 12) of cell lines, apparently independent
from the status of major genes that are mutated in HCC including
p53, p16INK4a, b-catenin and Axin1. Comparative studies with a
growth-sensitive Huh7 and growth-resistant Hep40 cell lines
showed that lithium induces growth arrest in Huh7 cells but not in
Hep40 cells. Lithium induced the accumulation of N-terminally
phosphorylated inactive form of GSK3b with concomitant
increase in b-catenin and b-catenin/TCF transcriptional activity
in both cell lines. This suggests that lithium-mediated HCC growth
inhibition is independent of its well-known stimulatory effect on
Wnt-b-catenin signaling. The main differences between Huh7 and
Hep40 responses to lithium treatment were observed at the levels
PKB/Akt and cyclin E proteins. Lithium induced depletion of both
proteins in growth-sensitive Huh7, but not in growth-resistant
Hep40 cells. PKB/Akt and Cyclin E are 2 major proteins that are
known to be constitutively active in HCC. The targeting of both
proteins with lithium may be the main reason why most HCC cells
are responsive to lithium-mediated growth inhibition, independent
of their p53, retinoblastoma and Wnt-b-catenin pathways. The
exploration of molecular mechanisms involved in lithium-medi-
ated growth inhibition in relation with PKB/Akt and cyclin E
downregulation may provide new insights for therapy of liver
tumors.
' 2005 Wiley-Liss, Inc.
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Lithium is the main therapeutic agent for the treatment of bipo-
lar disorders, but its mechanism of action is poorly understood.1
Mechanistic studies have shown that lithium affects profoundly
the embryonic development and tissue patterning in various organ-
isms.2 The effects of lithium on the embryonic development of
Xenopus is quite similar to the effects observed upon experimental
activation of Wnt-b-catenin pathway.2,3–6 This similarity is due to
the inhibitory effects of lithium on the activity of glycogen syn-
thase kinase-3b (GSK-3b) enzyme,7–9 which plays a key role in
the regulation of Wnt-b-catenin signaling pathway. In the absence
of Wnt signals, GSK-3b-mediated N-terminal phosphorylation is
required for ubiquitin-mediated degradation of b-catenin.10,11
Exposure of cells to either Wnt ligands or lithium treatment results
in the inhibition of GSK-3b activity, whereby leading to the cyto-
plasmic accumulation of b-catenin. Stabilized b-catenin forms
nuclear complexes with a family of lymphoid enhancer/T-cell
transcription factor (TCF) proteins, leading to the up-regulation of
TCF target genes.12–15
The wnt-b-catenin pathway is one of the most commonly acti-
vated signaling pathways in different tumor types, including hepa-
tocellular carcinoma (HCC). The aberrant activation of this
pathway may occur via different mechanisms, but it commonly
involves the cytoplasmic or nuclear accumulation of b-catenin
protein.16–25 Mutational inactivation of the APC gene is the main
cause of b-catenin accumulation in >80% of colorectal cancers.26
Oncogenic mutations almost always affecting the N-terminal
phosphorylation domain of b-catenin are rare in colorectal
cancers,26 but quite common in hepatoblastomas.21,27,28 In HCC,
b-catenin, Axin1 and p53 mutations are the main sources of b-cat-
enin accumulation.29–35 Thus, lithium seems to display an activity
(accumulation of b-catenin) that can mimic all known causes of
aberrant wnt-b-catenin activation in different types of cancer.
We studied the effects of lithium as an experimental drug for
activation of the wnt-b-catenin signaling pathway in HCC cell
lines. Our initial studies led us to unexpected finding that the lith-
ium-induced activation of this pathway leads to growth inhibition
rather than growth stimulation, independent of the status of wnt-b-
catenin pathway genes, in HCC cells. Further studies on selected
cell lines showed that lithium is able to activate wnt-b-catenin
pathway in HCC cells, but its additional inhibitory effects on
PKB/Akt and cyclin E proteins result in a cell cycle arrest, over-
riding any potential growth stimulatory effect that could be medi-
ated by this pathway. Our studies also provide experimental
evidence that lithium or lithium-like drugs are potential candidates
for therapy of liver tumors.
Material and methods
Cell lines
The origins and culture conditions of HCC cell lines used here
have been reported recently.51 Lithium treatment was carried out
in 12-well plates, 6-well plates or 10-cm culture dishes, depending
on the type of experiments. Cells were plated in normal medium
for overnight. The following day, the experiments were started by
removing the initial medium together with unattached cells, fol-
lowed by adding fresh medium supplemented with either LiCl or
NaCl. Different doses of LiCl (5–30 mM) were used. Unless
specified otherwise, negative controls were carried out in medium
supplemented with the same concentration of NaCl. For the study
of morphological changes, cells were grown on coverslips in
6-well plates, and examined under light microscope. Morphologi-
cal changes were recorded at different time points by taking digital
pictures. For growth assays with different HCC cell lines, 15,000
cells were resuspended in control medium, and plated into 12-well
plates. The following day, the medium was removed together with
unattached cells, and cells were incubated in a medium containing
either 20 mM LiCl or 20 mM NaCl for 4 days. Each experiment
was carried out in triplicate and the number of cells were counted
manually.
Transfections
Huh7 or Hep40 cells were seeded at a density of 1  105 cells/
well in a 6-well plate. After 24 hr, transfection was done by using
calcium-phosphate method. Two micrograms of pGL3-OT or
pGL3-OF reporter plasmids (supplied by Bert Vogelstein) were
Grant sponsor: TUBITAK; Grant sponsor: Turkish Association for
Research and Fight against Cancer; Grant sponsor: Bilkent University and
Turkish Academy of Sciences (TUBA).
*Correspondence to: Bilkent University, Department of Molecular
Biology and Genetics, 06800 Ankara-Turkey. Fax: þ90-312-266-5097.
E-mail: ozturk@fen.bilkent.edu.tr
Received 22 September 2004; Accepted after revision 16 November
2004
DOI 10.1002/ijc.20972
Published online 18 February 2005 inWiley InterScience (www.interscience.
wiley.com).
Int. J. Cancer: 115, 903–910 (2005)
' 2005 Wiley-Liss, Inc.
Publication of the International Union Against Cancer
cotransfected with 0.5 mg pEGFP-N2 expression vector (Clontech,
Palo Alto, CA) to check transfection efficiency. Sixteen hours
post-transfection, the medium was replaced with a fresh medium
containing 10 mM LiCl, 20 mM LiCl or 20 mM NaCl. After 48 hr
of treatment, percentage of transfected cells was calculated by
counting GFP-positive and GFP-negative cells, just before per-
forming luciferase assay. Luciferase Reporter Gene Assay, con-
stant light signal kit (Roche Diagnostics GmbH., Mannheim,
Germany) was used, as described by the supplier, and luciferase
activities were read with the Reporter1 Microplate Luminometer
(Turner BioSystems Inc., Sunnyvale, CA). Arbitrary units of luci-
ferase activity were subtracted from background signal and nor-
malized luciferase units were calculated by taking into account the
transfection efficiency of each transfection. All experiments were
carried out in triplicates.
Western blotting
Detergent-soluble cell lysates were prepared and used for West-
ern blot analysis, as described previously.51 Antibodies to b-cate-
nin (Santa Cruz Biotechnology, Santa Cruz, CA), Cyclin D1
(Santa Cruz Biotechnology), Cyclin E (Pharmingen, San Diego,
CA), GSK-3b (Pharmingen, San Diego, CA) and PKB/Akt, phos-
pho-Serine256 FKHR, PTEN, phospho-serine9 GSK-3b in PKB/
Akt sampler kit (Cell Signaling Technology, Inc., Beverly, MA),
CDK2 (Santa Cruz Biotechnology) CDK4 (Santa Cruz Biotech-
nology) and calnexin (Sigma, St. Louis, MO) were obtained com-
mercially. Monoclonal antibody to CK18 was kindly provided by
D. Bellet (Institut Gustave Roussy, Paris, France). To generate a
linear response in western blotting assays, we used appropriate
amounts of proteins from cell lysates for SDS-PAGE and an ECL
kit (Amersham Life Science, Inc., Piscataway, NJ) for detection of
antigen-antibody complexes. Equal protein loading was verified
by Western blot assay with CK18 or calnexin. Experiments were
repeated several times with different batches of cell lysates for
verification.
BrdU labeling and cell cycle analysis
For BrdU incorporation, cells were incubated with 30 mM BrdU
for 4 hr before fixation with ice-cold 70% ethanol for 10 min.
After DNA denaturation in 2 N HCl for 20 min, cells were incu-
bated with FITC-conjugated anti-BrdU antibody (DakoCytoma-
tion, Glostrup, Denmark), cells were counterstained with Hoechst
33258 (Sigma-Aldrich, Co., Taufkirchen, Germany). Pictures of
FITC and Hoechst 33258 fluorescences were taken with different
filter sets and images were merged using Adobe Photoshop 3.05
software.
For cell cycle analysis, asynchronously growing cells were har-
vested at 48 hr after addition of 20 mM NaCl or 20 mM LiCl. The
distributions of cells in different stages of the cell cycle were
quantified by flow cytometric cell cycle analysis of DNA content.
For DNA profiles, cells were harvested and fixed in 70% ethanol
at 48C. After washing away the ethanol, the cells were incubated
in a solution containing 10 mg/ml DNAse-free RNAse at 378C for
30 min, and then stained with 20 mg/ml propidium iodide solution
prepared in 0.5 mM Tris (Sigma-Aldrich, Taufkirchen, Germany),
1.5 mM Spermine tetrahydrochloride (Sigma-Aldrich), 0.1%
Nonidet P40 (Sigma-Aldrich) and 3.4 mM Trisodium citrate
(Sigma-Aldrich) at room temperature in the dark. At least 15,000
stained cells were acquired using CellQuest software by FACSCa-
libur cell sorter (Becton Dickinson, Mountainview, CA). Cell
cycle distributions were analyzed by using ModFit software and
cell cycle profiles were visualized using WinMDI v2.8 software
developed by Joseph Trotter (Scripps Research Institute, San
Diego, CA; http://facs.scripps.edu/software.html).
Tests for apoptosis
Cells were grown up to 72 hr in either LiCl- or NaCl-containing
medium, in parallel with normal culture medium. Apoptosis was
tested using NAPO and Annexin V assays, as described.37
RT-PCR and Real-Time PCR analyses of cyclin E transcripts
Total RNA was extracted and used for cDNA synthesis and
semi-quantitative RT-PCR analysis. The detection of cyclin E and
GAPDH mRNA levels were carried out as described previously.51
The primers were: Cyclin E-F (50-TTGACCGGTATATGGCGA-
CACAAG-30) and Cyclin E-R (50-ATGATACAAGGCCGAAGC-
AGCAAG-30) for the detection of Cyclin E expression; GAPDH -F
(50-GGCTGAGAACGGGAAGCTTGTCAT-30) and GAPDH -R
(50-CAGCCTTCTCCATGGTGGTGAAGA-30) for the detection
of GAPDH expression. The amplification cycle included a denatu-
ration step of 948C for 5 min, followed by 32 cycles of (for Cyclin
E) or 24 cycles of (for GAPDH) 948C for 30 sec, 628C for 30 sec,
728C for 30 sec and concluded with a final primer extension step
of 728C for 5 min.
The iCycler iQ real-time PCR detection system (Bio-Rad,
Richmond, CA) was used for real-time PCR of cyclin E and
GAPDH. The detection of amplification product was detected with
SYBR Green I, using the primer pairs described above.












Huh7 Normal p53 (Y220C) Normal 0.2 6 0.1 17.9 6 3.0 98.9
SK-Hep1 p16INK4a (HD) p14ARF(HD) Normal 0.5 6 0.2 35.3 6 7.4 98.6
SNU-475 p16INK4a (PM) p53(N239D/C275R/
N288S)
Axin1 (HD) 0.46 0.3 8.3 6 0.3 95.2
SNU-182 Normal p53 (S215I) Normal 0.9 6 0.0 8.4 6 0.4 89.3
p53 (L164X)
SNU-387 p16INK4a (HD) p14ARF(HD) Normal 0.7 6 0.3 5.2 6 0.8 86.5
PLC/PRF/5 Normal p53 (R249S) Axin1 (DE4/) 2.76 0.9 18.0 6 2.2 85.0
Mahlavu Normal p53 (R249S) Normal 6.7 6 1.6 41.3 6 5.3 83.8
b-catenin
HepG2 Normal Normal (DE3/wt) 0.56 0.0 2.5 6 0.7 80.0
Hep3B pRb (undetected) p53 (HD) Normal 0.5 6 0.2 1.7 6 0.3 70.6
p53 (K139R/A161T)
SNU-449 p16INK4a (HD) p14ARF (HD) Normal 4.76 1.0 10.2 6 1.1 53.9
FOCUS pRb (decreased) p53 (undetected) Normal 6.0 6 0.0 12.3 6 1.2 51.2
Axin1
Hep40 pRb (undetected) p53 (Mutant protein) (R454H)5 3.16 0.8 3.7 6 0.8 16.2
1From Ref.51.–2Data for b-catenin from Ref. 35, data for Axin1 from our study.–3Number of cells ( 104) 6 SD (n ¼ 3) at Day 4 of culture
in the presence of 20 mM LiCl or 20 mM NaCl.–4Based on the comparison with LiCl vs. NaCl treatment.–5The functional significance of this
missense mutation that affects an evolutionarily conserved residue is not known. WT, wild-type; HD, homozygous deletion; PM, promoter
hypermethylation.
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Axin1 mutation analysis
First strand cDNAs of HCC cell lines were prepared by Revert-
Aid First Strand cDNA synthesis kit (MBI Fermantas GmbH,
St-Leon-Rot, Germany) and screened for possible mutations in a
region spanning part of exon 2, exon 3, and 4 and part of 5. This
region that encodes amino acids 325–433 (according to GenBank
entry: AF009674) is known to be affected by 50% of Axin1 gene
mutations that have been identified in HCC.32–34 Cell line cDNAs
were amplified and Axin1 cDNA-positive samples (all except
SNU475) were subjected to direct sequencing (Perkin-Elmer Big-
Dye Terminal Cycle Sequencing) in both directions using the
AxcDNA-Forward (50-CAACGACAGCGAGCAGCAGCAGA-3)
and AxcDNA-Reverse (50-GAGGCAGCTTGTGACACGGC-3)
primer pair. Standard conditions for PCR were 5 pmol/ml each pri-
mer, 200 mM dNTPs, 1 PCR buffer containing 1.5 MgCl2, 1%
DMSO and 0.25 U Taq DNA polymerase.
Results
Lithium inhibits the growth of most hepatocellular carcinoma cells in
p53, p14ARF, p16INK4a, b-catenin and Axin1-independent manner
It is now well established that 2 major components of the Wnt-
b-catenin pathway, namely b-catenin and Axin1 genes are fre-
quent targets for mutation in HCC, suggesting that the constitutive
activation of Wnt-b-catenin pathway may play a major role in
these cancers. The effects of constitutively activated Wnt-b-cate-
nin pathway, however, are largely unknown in HCC. To study the
hepatocellular effects of Wnt-b-catenin signaling, we used an
experimental system based on the use of lithium as an inhibitor of
GSK-3b enzyme. First, we collected data on the status of p53,
p14ARF, p16INKa, Retinoblastoma, Axin1 and b-catenin genes in a
panel of 12 HCC cell lines. As shown in Table I, the status of
these genes, except Axin1, was already known. Axin1 gene was
analyzed as described in Material and Methods section. In addition
to mutations reported previously in SNU-475 and PLC/PRF/5 cell
lines, Hep40 cell line displayed a missense mutation in a con-
served amino acid residue (R454H) of Axin1. There was no
detectable Axin1 mutation in other cell lines listed (Table I). Next,
we studied growth response of the panel of HCC cell lines. Equal
number of cells were plated from each cell line and cultivated in
the presence of either 20 mM LiCl or 20 mM NaCl (control
medium) for 4 days, and the number of cells was counted man-
ually. The results of these cell growth experiments were shown in
Table I. Of 12 cell lines tested, 9 (75%) responded with a strong
growth inhibition ranging between 70–99%. The remaining 3 cell
lines were partially resistant to lithium-induced growth inhibition
as their growth inhibition was 16–54%. None of the cell lines
FIGURE 1 – Lithium causes inhibition of
GSK-3b, stabilization of b-catenin, and
activates b-catenin/TCF reporter pGL3-
OT. (a) Huh7 cells were incubated in the
presence of either 20 mM LiCl or 20 mM
NaCl, and cell lysates were subjected to
Western blot assays for total GSK-3b,
phospho-serine9- GSK-3b, b-catenin and
cytokeratin 18 (CK18) at 0, 24 and 48 hr,
respectively. LiCl has no effect on total
GSK-3b levels, but it causes strong accu-
mulation of phospho-serine9- GSK-3b, as
well as a weak but reproducible accumula-
tion of b-catenin. CK18 was used as a
loading control. (b) Cells were treated with
LiCl or NaCl and tested for b-catenin/TCF
transcriptional activity using pGL3-OT
(OT) reporter plasmid. The pGL3-OF
(OF) reporter was used as a negative con-
trol. Normalized luciferase activity is the
mean 6 SD from 3 independent experi-
ments. LiCl causes dose-dependent induc-
tion of pGL3-OT reporter activity.
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tested responded to lithium treatment by a growth increase
(Table I).
These observations showed that lithium was an efficient growth
inhibitor of most HCC cell lines. To our surprise, there was no
obvious association between the status Wnt-b-catenin pathway
genes (b-catenin and Axin1) in these cell lines and their response
to lithium treatment. Similarly, lithium response also seemed to be
independent of p53 gene and INK4a/ARF locus. Most of growth-
responsive cell lines (8 of 9) expressed Retinoblastoma (pRb) pro-
tein, whereas 2 of 3 growth-resistant cell lines lacked pRb or had
decreased expression (Table I).
To further study growth-inhibitory effects of lithium on HCC
cell lines, we carried out comparative studies with 2 selected cell
lines; Huh7 that responded to lithium by a dramatic growth inhibi-
tion (99%), and Hep40 that was the most growth-resistant cell
line displaying only 16% growth inhibition.
Lithium activates Wnt-b-catenin pathway by inhibiting GSK-3b
and inducing b-catenin accumulation in Huh7 hepatocellular
carcinoma cells
Lithium activates Wnt-b-catenin signaling as a direct GSK-3b
inhibitor, as well as by inducing the levels of N-terminally
(Serine9) phosphorylated inactive form of the enzyme.36 There-
fore, we first tested the levels of phospho-serine9-GSK-3b by
Western blotting. As shown in Figure 1a, the levels of phospho-
serine9-GSK-3b displayed a dramatic and sustained increase. In
NaCl-treated control cells, there was no accumulation of phospho-
serine9-GSK-3b levels, instead there was a progressive decrease,
most probably due to cell proliferation. Lithium not only inhibited
the decrease of phospho-serine9-GSK-3b levels that occurs in pro-
liferating cells, but also caused a strong accumulation of this inac-
tive form. As the total levels of GSK-3b did not change under
these conditions (Fig. 1a), it is highly likely that the accumulation
of phosphorylated/inactive form of GSK-3b caused a depletion of
the nonphosphorylated/active form of the enzyme. We then tested
whether lithium-induced inactivation of GSK-3b affected b-cate-
nin protein levels. As shown in Figure 1a, there was a weak but
sustained accumulation of b-catenin protein levels, despite its rela-
tively high basal levels.
As b-catenin binds to TCF/Lef transcription factors to activate
Wnt-responsive genes, we evaluated the ability of LiCl to activate
Wnt-dependent transcription using TCF/Lef reporter plasmid
pGL3-OT.12 Huh7 cells were treated with 10 or 20 mM LiCl up to
48 hr, and b-catenin/TCF transcriptional activity was tested. NaCl
treatment was used as a negative control. As shown in Figure 1b,
Huh7 cells displayed a low, but detectable pGL3-OT reporter activ-
ity in the absence of lithium treatment, suggesting that b-catenin/
TCF transcriptional activity is weakly positive in this cell line. The
treatment with 10 mM and 20 mM LiCl resulted in 2.5- and 10-fold
increases of pGL3-OT activity, respectively. The pGL3-OF reporter
(containing mutant-binding sites) displayed only background activ-
ity, with no change with lithium treatment, as expected.
These results demonstrated that lithium causes the accumulation
of phosphorylated/inactive forms of GSK-3b in Huh7 cells, with a
concomitant accumulation of b-catenin levels, as well as an
increase in b-catenin/TCF reporter activity, similarly to its previ-
ously reported effects in 293T kidney epithelial cells.36
Lithium affects morphology and proliferation of Huh7 cells
We studied the effects of lithium treatment on the morphology
and growth properties of Huh7 cells. These cells responded to lith-
ium treatment with the formation of tightly clustered cells
(Fig. 2a). At 20 mM of lithium treatment, there was an increase in
nucleus/cytoplasm ratios, sometimes accompanied with multi-
nuclear cell formation. These morphological changes were spe-
cific to lithium, as NaCl-treated cells displayed no morphological
changes (Fig. 2a). Representative pictures of cells shown in
Figure 2a were taken at 72 hr. The findings were similar at 48 hr
(data not shown). Lithium-induced morphological changes were
not associated with programmed cell death, at least for 72 hr.
Huh7 cells display characteristic features of apoptosis (nuclear
condensation, membrane blobbing) as reported previously,37
which are easily distinguished from the morphology shown in
Figure 2a. In addition, we carried out apoptosis tests in these cell
line under lithium-treatment, using 2 independent tests (NAPO
assay37 and Annexin V staining). There was no significant change
in the number of apoptotic figures under lithium-treatment, as
compared to control and NaCl-containing cultures that remained
low (<1%) during 72 hr of culture (data not shown).
To test whether lithium affects the growth of Huh7 cells by
inhibiting their proliferation, first, we studied DNA synthesis by
BrdU incorporation assay. Huh7 cells were incubated in the pres-
ence of either 20 mM LiCl or 20 mM NaCl up to 48 hr. At time
44 hr, BrdU was added into culture medium, and cells were incu-
bated for an additional 4 hr in the presence of BrdU. The immuno-
fluorescence staining of fixed cells for BrdU indicated that DNA
FIGURE 2 – Lithium changes the morphology and inhibits the prolif-
eration of Huh7 cells. (a) Huh7 cells were incubated in the absence
(control) or in the presence of either LiCl or NaCl, and light micro-
scope pictures of live cells were taken at 72 hr. Lithium treatment
causes tight clustering of cells with scanty cytoplasm some of which
have multiple nuclei. This effect is more pronounced with 20 mM
LiCl, and no such effect is seen with 20 mM NaCl. (b) Huh7 cells
were grown as described in (a) for 44 hr, then incubated in the pres-
ence of BrdU for an additional 4 hr, fixed and immunostained for
BrdU. Nuclear DNA was counterstained with Hoechst 33258. BrdU-
positive and BrdU-negative nuclei stain green and blue, respectively.
Note strong inhibition of BrdU incorporation under lithium treatment.
(c) Huh7 cells were grown as described in (a) for 48 hr, fixed, DNA-
stained with proprium iodide, subjected to flow cytometry, and cell
cycles profiles were visualized. The peak of G2/M phase cells
decreased, whereas G1/S fraction increased with lithium treatment.
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synthesis was severely impaired after 48 hr of lithium treatment.
The degree of DNA synthesis inhibition was quantified by manual
counting of BrdU-positive cells. After 4 hr of continuous labeling
with BrdU, 33% 6 4 (n ¼ 3) of NaCl-treated control cells dis-
played positive staining. In contrast, 4 hr of continuous labeling
with BrdU yielded only 15% 6 2 (n ¼ 3) positivity with lithium-
treated cells. Representative pictures of BrdU experiments were
shown in Figure 2b. Flow cytometric analysis of distribution of
cells with different DNA contents suggested that lithium-treated
cells accumulate at G1/S phase of the cell cycle. Although an
accurate calculation of ratios of cells at G1, S and G2/M phases
was not possible due to heterogeneous DNA content and lithium-
induced clustering of cells, representative data shown in Figure 2c
shows that cells at G2/M phase shift toward G1/S peak under LiCl
treatment, but not with NaCl treatment. These observations, com-
bined with BrdU experiment that shows strong inhibition of DNA
synthesis, are in favor of a lithium-induced G1/S cell cycle arrest.
Lithium induces cyclin E depletion in growth-sensitive Huh7,
but not in growth-resistant Hep40 cells
Cyclin D1 and cyclin E are involved in the control of G1
phase of the cell cycle. In addition, cyclin D1 is known to be
upregulated by Wnt-b-catenin signaling.14 We first tested pro-
tein levels of these G1 cyclins in lithium-treated Huh7 cells. As
shown in Figure 3a, lithium-treated Huh7 cells displayed a mod-
erate increase in cyclin D1 levels. More interestingly, lithium
treatment caused a dramatic fall in the levels of cyclin E protein
in these cells that was detected at both 24 hr and 48 hr after
lithium treatment (Fig. 3a). There was no change in the levels
of cyclin-dependent kinase 4 (CDK4) and CDK2 levels under
these conditions (data not shown). To test whether the progres-
sive decrease of cyclin E protein levels was due to a decrease
in cyclin E mRNA levels, we carried out RT-PCR and quantita-
tive PCR analyses. As shown in Figure 3b, cyclin E transcript
levels also decreased with lithium treatment. The degree of
cyclin E transcript downregulation was calculated by additional
experiments using real-time PCR. Progressively diluted cDNA
preparations obtained from NaCl-treated cells were subjected to
real-time PCR, in comparison with samples from LiCl-treated
cells. Undiluted samples from LiCl-treated cells provided a sig-
nal that was equal to that of a 16-fold diluted samples from
NaCl-treated cells (data not shown). This provided evidence for
at least 15-fold inhibition of cyclin E mRNA levels by lithium
in Huh7 cells.
To test whether the effects of lithium were dose-dependent,
Huh7 cells were incubated for 48 hr, in medium supplemented
with 5, 10, 20 or 30 mM LiCl, in comparison with normal
medium. As shown in Figure 4, cyclin E levels decreased progres-
sively, as the levels of LiCl were raised from 0–30 mM.
These studies indicated that lithium is able to cause a depletion
of cyclin E protein in Huh7 cells, and this effect is due, at least in
part, to a dramatic fall in cyclin E transcripts, probably because of
a transcriptional inhibition, as cyclin E transcripts are better
known for transcriptional regulation.38
As cyclin E is required for the transition of cells through G1
to S phase, inhibition of cyclin E expression is probably respon-
sible, at least partially, from lithium-induced growth inhibition
of Huh7 cells, and most probably other HCC cell lines that
responded to lithium treatment (Table I). If our hypothesis is
correct, growth-resistant Hep40 cells should respond to lithium
treatment differently. We carried out similar studies in Hep40
cells. First, we tested whether lithium was able to activate wnt-
b-catenin signaling in Hep40 cells using b-catenin/TCF reporter
assay. As shown in Figure 5a, lithium was able to induce
pGL3-OT reporter activity >6-fold with 20 mM in Hep40 cell
line. Transcriptional activation of b-catenin/TCF in Hep40 cells
was accompanied with accumulation of phospho-serine9-GSK-
3b, suggesting that the effects of lithium on wnt-b-catenin sig-
naling were comparable between Hep40 and Huh7 cell lines.
Lithium treatment had no effect on cyclin E protein levels in
Hep40 cells, unlike Huh7 cells (Fig. 5b). One of the main dif-
ferences between growth-responsive Huh7 and growth-resistant
Hep40 cells was at the level of cyclin E expression. This sug-
gests that lithium is able to inhibit the growth of some HCC
cells such as Huh7 cells by interfering with the expression of
cyclin E, a critical protein involved in the transition from G1 to
S phase of the cell cycle.
FIGURE 4 – Lithium effect is dose-dependent. Huh7 cells were
treated with gradually increasing concentrations of LiCl (0–30 mM)
for 48 hr, and protein lysates were subjected to Western blot assay for
cyclin E, followed by calnexin as an equal loading control. Note the
dose-dependent depletion of Cyclin E under lithium treatment.
FIGURE 3 – Lithium induces the accumulation of cyclin D1, but
provokes a depletion of cyclin E and PKB/Akt proteins in Huh7 cells.
(a) Cells were treated with LiCl or NaCl (20 mM each) for 48 hr, and
protein lysates, collected at 0 hr, 24 hr and 48 hr, were subjected to
Western blot assays for cyclin D1, cyclin E, PKB/Akt, PTEN, phos-
pho-serine256 FKHR and CK18. Note the accumulation of cyclin D1,
but depletion of Cyclin E and PKB/Akt levels under lithium treatment.
As an indication of PKB/AKT inhibition by lithium treatment, phos-
pho-serine256 FKHR levels also decreased. PTEN levels did not
change. CK18 was used as a loading control. (b) Cyclin E and
GAPDH transcripts were tested by RT-PCR analysis of total RNA
extracted from LiCl- and NaCl-treated Huh7 cells at 0 hr, 24 hr and
48 hr. Lithium caused a decrease in Cyclin E mRNA levels, in parallel
to the depletion of its protein levels shown in (a). Real-time PCR anal-
ysis of Cyclin E mRNA indicated a 16-fold decrease under lithium
treatment.
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Lithium depletes PKB/Akt in Huh7, but not in Hep40 cells
The molecular mechanisms of lithium-mediated inhibition of
cyclin E expression are presently unknown, but this could be due
to the inhibition of an upstream signaling event by lithium. P13K/
Akt pathway has been implicated recently in control of HCC cell
proliferation.39 Therefore, we also tested protein levels of PKB,
also called Akt (PKB/Akt) protein in Huh7 and Hep40 cells.
Lithium caused a depletion of PKB/Akt protein levels in Huh7
(Fig. 3a), but not in Hep40 (Fig. 5b) cells. Lithium-mediated
depletion of PKB/Akt protein levels was accompanied with a
decrease in the phosphorylation of its substrate FKHR40 in Huh7
cells, providing indirect evidence that PKB/Akt is constitutively
active in this cell line, but its activity is inhibited by lithium treat-
ment. The protein PTEN that acts as an inhibitor of PI3K/Akt sig-
naling41 did not show detectable change under these conditions
(Fig. 3a). Taken together, these observations provide evidence that
the inhibition of PKB/Akt or cyclin E expression is implicated in
lithium-induced growth control of HCC cells.
Discussion
Our studies on hepatocellular response to lithium show several
interesting novel findings. First, HCC cell lines are in general
responsive to lithium treatment. As exemplified by results pre-
sented for Huh7 and Hep40 cells, lithium induces the accumula-
tion of inactive phospho-serine9 GSK-3b with concomitant
activation of Wnt-b-catenin signaling. Most strikingly, lithium
was able to inhibit strongly (>70% inhibition) the growth of 9/12
cell lines tested. This growth-inhibitory response did not require
functional p53, p16INKa, p14ARF, b-catenin or Axin1 genes. This
particular growth inhibitory response was accompanied with a
depletion of both cyclin E and PKB/Akt proteins in Huh7, a
growth-sensitive cell line, whereas there was no such effect in
Hep40, a growth-resistant cell line. Cyclin E depletion is appa-
rently regulated at the transcriptional level as we detected 16-fold
decrease of cyclin E transcripts under lithium treatment. This
defect in cyclin E expression is likely to play the major role in
growth inhibition, as Huh7 cells underwent DNA synthesis inhibi-
tion as well as an accumulation at the G1/S phase of the cell cycle.
This is not unexpected, as cyclin E together with cdk2 is required
for the entry of cells from G1 to S phase. Cyclin E is one of the
key genes in hepatocellular carcinogenesis, as its upregulation is
frequent42 and its activation may be closely related to the histopa-
thologic grade and progression of HCC.43 Moreover, suppression
of cyclin E overexpression in HCC by RNAi leads to inhibition of
DNA synthesis and tumor growth in vivo.44 The other protein tar-
geted by lithium, PKB/Akt is one of the major kinases that inacti-
FIGURE 5 – Lithium activates Wnt-b-catenin
signaling, but has no effect on cyclin E and PKB/
Akt proteins in growth-resistant Hep40 cells.
(a) After incubation in the presence of either
20 mM LiCl or 20mM NaCl, Hep40 cell lysates
were subjected to reporter assay for b-catenin/
TCF-mediated transcription, as described in
Figure 1b. The pGL3-OT luciferase activity was
induced in the presence of LiCl in a dose-
dependent manner. (b) Cells were treated with
LiCl or NaCl (20 mM each) for 48 hr, and pro-
tein lysates, collected at 0 hr, 24 hr and 48 hr,
were subjected to Western blot assays for phos-
pho-serine9-GSK-3b, total GSK-3b, cyclin E,
PKB/Akt and CK18. Lithium caused accumula-
tion of phospho-serine9-GSK-3b, but it had no
effect on total GSK-3b, cyclin E and PKB/Akt
levels. CK18 was used as a loading control.
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vates GSK3b by N-terminal phosphorylation, although additional
kinases have also been implicated.45 Thus, before discussing the
implications of lithium-mediated PKB/Akt inactivation, accumu-
lation of N-terminally phosphorylated GSK3b in Huh7, under the
same conditions deserves further consideration. It has been
reported recently that lithium induces GSK3b N-terminal phos-
phorylation through direct inhibition of GSK3b itself. This lith-
ium-induced N-terminal phosphorylation is based on a mechanism
regulating GSK3b-dependent protein phosphatase 1-inhibitor 2
complex that does not require PKB/Akt.36 Huh7 cells may use
such a mechanism to induce N-terminally phosphorylated inactive
GSK3b, upon exposure to lithium, despite the inactivation of
PKB/Akt protein.
Inactivation of GSK3b and activation of wnt-b-catenin signal-
ing is probably one of the mechanisms that explain moderate
increase in the levels of cyclin D1 in both Huh7 and Hep40 cells,
as this cyclin D1 gene is a transcriptional target for wnt-b-catenin
signaling,14 and GSK-3b triggers cyclin D1 degradation by phos-
phorylation.46 Lithium-mediated increase in cyclin D1 levels was
not sufficient, however, to stimulate cell proliferation of the 2 cell
lines studied. Indeed, the data with Huh7 strongly suggests that
this wnt-b-catenin-related effect of lithium is override by a con-
comitant drop in cyclin E levels due to a loss of cyclin E tran-
scripts, which leads to a cell cycle arrest, instead of cell
proliferation.
The mechanisms by which cyclin E transcripts are downregu-
lated by lithium treatment in Huh7 cells are presently unknown,
but it could be related to downregulation of PKB/Akt function in
these cells. Lack of both PKB/Akt and cyclin E downregulation in
growth-resistant Hep40 cells under the same conditions further
supports this hypothesis, although a direct proof remains missing.
PKB/Akt, a kinase with multiple cellular functions, including met-
abolic control and cell survival, is a critical component of PI3K/
Akt pathway that is deregulated in different cancer types.47
Recently, PI3K/PKB/Akt signaling acting via inhibition of
C/EBPa has been described as a molecular mechanism for the
development of liver tumors.39 The studies by Wang et al.39
clearly establish that PKB/Akt is constitutively active in HCC
cells and this activation blocks the growth inhibitory activity of
C/EBPa through the PP2A-mediated dephosphorylation. C/EBPa
blocks proliferation of hepatocytes by 2 distinct mechanisms;
inhibition of CDK4/CDK2 and repression of E2F.48,49 Accord-
ingly, inhibition of PKB/Akt by RNA interference, or by PI3K-
inhibitor Wortmannin treatment induces growth arrest in HCC
cells. The effects that we observed with Huh7 cells parallel with
these observations in terms of lithium-mediated downregulation of
PKB/Akt and growth arrest. In addition, we showed that Wort-
mannin significantly inhibits the growth of Huh7 cells (data not
shown). The decrease of cyclin E transcripts upon PKB/Akt deple-
tion in these cells is probably related to the inhibitory effects of C/
EBPa on CDK4 and E2F activities. In confirmation of studies
reported by Wang et al.39 our preliminary studies show that both
Huh7 and Hep40 express C/EBPa (data not shown). Interestingly,
retinoblastoma protein that is required for C/EBPa-mediated E2F
repression is expressed in Huh7, but not in Hep40 cells (Table I).
The activity of PKB/Akt is known to be regulated by its P13K-
dependent phosphorylation.47 Regulation by the control of PKB/
Akt protein levels has also been described as a novel mecha-
nism.50 Interestingly, mTOR pathway seems to be involved in this
process, as inhibition of mTOR by rapamycin induces PKB/Akt
degradation in endothelial cells.50 Presently, it is not known,
whether lithium utilizes a similar mechanism to decrease PKB/
Akt protein levels in Huh7 cells.
In conclusion, our observations provide evidence for hereto
unknown effects of lithium; the downregulation of levels of PKB/
Akt and cyclin E protein. These 2 proteins are required for cell
survival and proliferation. These newly described effects may
count, as least partially, for the ability of lithium to prevent the
growth of many HCC cells, apparently independent from the
mutational status of major HCC genes such as p53, p16INK4a and
b-catenin (Table I). The exploration of molecular mechanisms
involved in lithium-mediated HCC growth inhibition in relation
with PKB/Akt/cyclin E downregulation may provide new insights
for therapy of liver tumors.
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